|
91 |
Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis
Enthalten in BioDrugs Bd. 37, 23.3.2023, Nr. 3, date:5.2023: 409-420
|
|
|
|
92 |
In Vitro Biological Characterization of Recombinant Insulin Aspart from Biogenomics and Originator Insulin Aspart
Enthalten in BioDrugs Bd. 37, 7.6.2023, Nr. 5, date:9.2023: 709-719
|
|
|
|
93 |
Incidence of and Reasons and Determinants Associated with Retransitioning from Biosimilar Etanercept to Originator Etanercept
Enthalten in BioDrugs Bd. 35, 26.10.2021, Nr. 6, date:11.2021: 765-772
|
|
|
|
94 |
Interchangeability and adverse events in originator-rituximab and its biosimilar (CT-P10) among rheumatic patients: a real-life experience
Enthalten in Internal and emergency medicine Bd. 18, 24.2.2023, Nr. 3, date:4.2023: 791-799
|
|
|
|
95 |
Kein Nachteil durch Wechsel zwischen Biosimilar und Originator
Enthalten in Hautnah / Dermatologie Bd. 34, 12.5.2018, Nr. 3, date:5.2018: 28-29
|
|
|
|
96 |
Label discrepancies between originator and generic drugs impact safety
Enthalten in Reactions weekly Bd. 1802, 2.5.2020, Nr. 1, date:5.2020: 8
|
|
|
|
97 |
Non-medical Switching from Originator Tumor Necrosis Factor Inhibitors to Their Biosimilars: Systematic Review of Randomized Controlled Trials and Real-World Studies
Enthalten in Advances in therapy Bd. 35, 6.8.2018, Nr. 9, date:9.2018: 1295-1332
|
|
|
|
98 |
Non-pharmacological Effects in Switching Medication: The Nocebo Effect in Switching from Originator to Biosimilar Agent
Enthalten in BioDrugs Bd. 32, 29.9.2018, Nr. 5, date:10.2018: 397-404
|
|
|
|
99 |
Originator-to-biosimilar non-medical switch may not yield such great cost savings
Enthalten in PharmacoEconomics & outcomes news Bd. 892, 27.11.2021, Nr. 1, date:11.2021: 17
|
|
|
|
100 |
Outcomes Following Adalimumab Bio-originator to Biosimilar Switch—A Comparison Using Real-world Patient- and Physician-Reported Data in European Countries
Enthalten in Rheumatology and therapy Bd. 10, 12.1.2023, Nr. 2, date:4.2023: 433-445
|
|
Administration
